Sinovac Biotech: +56% today !

BEIJING, Aug. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA),
 a leading provider of biopharmaceutical products in China, announced 
today that Sinovac's H1N1 vaccine has passed the experts evaluation 
organized by State Food and Drug Administration (SFDA).
The vaccine is expected to obtain the production license within this week.